Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04360954 · ClinicalTrials.gov registry record
Evaluation of Antibody Tests for COVID-19
A clinical trial of Coronavirus and COVID, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- 461
- Enrollment target
- 1
- Study location
NCT04360954: Completed study of Coronavirus and COVID, sponsored by Washington University School of Medicine.
NCT04360954 is a study of Coronavirus and COVID that has completed, run by Washington University School of Medicine. The registered enrollment target is 461 participants, below the 1,382-participant average among 20 other Coronavirus trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04360954, a study of Coronavirus and COVID, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- 461 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the sensitivity and specificity of several marketed commercial or prototype test kits for antibody to SARS-CoV-2. The focus will be on rapid-format, point-of-care antibody test kits that detect both IgM and IgG antibodies to recombinant viral proteins. Note: No voluntary enrolment into this study will be conducted; all testing is to be conducted anonymously.
Primary Outcome
Test sensitivity relative to RT-PCR for acute samples; sensitivity relative to ELISA for convalescent samples.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Diagnostic test
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 461 participants |
| Start Date | 2020-04-23 |
| Est. Completion | 2020-07-08 |
What the finished NCT04360954 record still lists
NCT04360954 is an observational study that tracks outcomes without assigning an intervention. The registered 461 participants enrollment target is mid-sized for trials with a published cap, below the 1,382-participant average among 20 other Coronavirus trials with a reported enrollment target (67% lower).
The record links to 2 conditions, with Coronavirus appearing as the primary indexed condition, and to 1 intervention - of which Diagnostic test is the first listed.
NCT04360954 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT04360954 about?
NCT04360954 is a clinical study titled "Evaluation of Antibody Tests for COVID-19". The purpose of this study is to evaluate the sensitivity and specificity of several marketed commercial or prototype test kits for antibody to SARS-CoV-2. The focus will be on rapid-format, point-of-care antibody test kits that detect both IgM and IgG antibodies to recombinant viral proteins. Note:...
What is the current status of trial NCT04360954?
This trial is currently completed. The enrollment target is 461 participants. The study started on 2020-04-23. Estimated completion is 2020-07-08.
What conditions does trial NCT04360954 study?
This clinical trial studies the following conditions: Coronavirus, COVID.
What interventions are being tested in trial NCT04360954?
The interventions under investigation include: Diagnostic test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04360954?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04360954 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronavirus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04360954's enrollment target sits among peer trials
461 7th of 20 higher than 14 of 20 other Coronavirus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronavirus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses
RECRUITING
-
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
RECRUITING · NA
-
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
RECRUITING · Phase 3
-
ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers
RECRUITING
-
A Study to Explore the Role of Gut Flora in COVID-19 Infection
RECRUITING
-
Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04546399 · 461 participants · Phase 2
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT00949819 · 462 participants
Active Surveillance for Cancer of the Prostate (ASCaP)
- NCT05126277 · 462 participants · Phase 3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI